Mitsubishi UFJ Asset Management
ALLO icon

Mitsubishi UFJ Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
547,189
+118,489
+28% +$260K ﹤0.01% 841
2026
Q1 		$1.05M Buy
428,700
+289,800
+209% +$581K ﹤0.01% 798
2025
Q4 		$188K Hold
138,900
– – ﹤0.01% 1029
2025
Q3 		$172K Hold
138,900
– – ﹤0.01% 1003
2025
Q2 		$157K Sell
138,900
-125,165
-47% -$166K ﹤0.01% 1012
2025
Q1 		$386K Buy
264,065
+10,489
+4% +$19.8K ﹤0.01% 875
2024
Q4 		$548K Buy
253,576
+16,880
+7% +$41.6K ﹤0.01% 861
2024
Q3 		$663K Sell
236,696
-9,238
-4% -$24.6K ﹤0.01% 835
2024
Q2 		$573K Buy
245,934
+28,439
+13% +$83.9K ﹤0.01% 834
2024
Q1 		$972K Sell
217,495
-3,599
-2% -$15K ﹤0.01% 807
2023
Q4 		$736K Buy
221,094
+37,131
+20% +$105K ﹤0.01% 843
2023
Q3 		$583K Hold
183,963
– – ﹤0.01% 875
2023
Q2 		$914K Buy
183,963
+18,585
+11% +$101K ﹤0.01% 828
2023
Q1 		$817K Buy
165,378
+1,933
+1% +$12.4K ﹤0.01% 840
2022
Q4 		$941K Sell
163,445
-8,778
-5% -$81.3K ﹤0.01% 813
2022
Q3 		$1.86M Buy
172,223
+481
+0.3% +$6.54K 0.01% 709
2022
Q2 		$1.96M Buy
171,742
+15,042
+10% +$134K 0.01% 713
2022
Q1 		$1.43M Buy
156,700
+1,874
+1% +$19.5K 0.01% 791
2021
Q4 		$2.37M Buy
154,826
+53,453
+53% +$943K 0.01% 723
2021
Q3 		$2.6M Hold
101,373
– – 0.01% 692
2021
Q2 		$2.64M Buy
101,373
+41,688
+70% +$1.19M 0.01% 689
2021
Q1 		$2.11M Buy
59,685
+3,785
+7% +$128K 0.01% 683
2020
Q4 		$1.41M Buy
55,900
+25,187
+82% +$821K 0.01% 714
2020
Q3 		$1.16M Buy
30,713
+11,366
+59% +$429K 0.01% 695
2020
Q2 		$828K Sell
19,347
-21,638
-53% -$783K 0.01% 719
2020
Q1 		$797K Buy
40,985
+17,110
+72% +$408K 0.01% 663
2019
Q4 		$620K Buy
23,875
+18,712
+362% +$515K 0.01% 758
2019
Q3 		$141K Buy
5,163
+994
+24% +$28.3K ﹤0.01% 870
2019
Q2 		$112K Buy
+4,169
New +$116K ﹤0.01% 907

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Mitsubishi UFJ Asset Management's ALLO Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management increased its Allogene Therapeutics (ALLO) stake by 28% in Q2 2026, buying an estimated $260K and bringing the position to 547,189 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #841.

Mitsubishi UFJ Asset Management first reported a position in ALLO in Q2 2019 and has held it in 29 quarters since. The position peaked at $2.64M in Q2 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 547,189 shares of Allogene Therapeutics worth $1.14M as of Q2 2026.
  • Mitsubishi UFJ Asset Management bought 118,489 Allogene Therapeutics shares in Q2 2026, an estimated $260K.
  • Allogene Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #841 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Mitsubishi UFJ Asset Management's Allogene Therapeutics position peaked at $2.64M in Q2 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.